Threonic Acid: Brain Effects, Dosing, and Human Trials

Threonic acid is a small, four-carbon sugar acid that your body produces naturally when it breaks down vitamin C. It would be an obscure footnote in biochemistry if not for one unusual property: when bonded to magnesium, it appears to carry that mineral across the blood-brain barrier far more effectively than other magnesium compounds. That discovery, first reported in animal studies around 2010, launched threonic acid from metabolic curiosity into the center of a growing supplement market and an active line of neuroscience research. But threonic acid’s story extends well beyond brain health, touching bone mineralization, hair biology, and even its potential as a biomarker for oxidative stress.

Where Threonic Acid Comes From

Threonic acid is what you get when vitamin C (ascorbic acid) breaks apart. More precisely, when ascorbic acid reacts with oxygen, the molecule splits between its second and third carbon atoms, yielding oxalic acid on one side and threonic acid (or its close relatives, like threonolactone and methyl threonate) on the other.¹ This happens constantly in your body as vitamin C does its work as an antioxidant. It also happens in food, in laboratory solutions, and in industrial processes. Because of this, threonic acid is considered an endogenous compound, meaning it is a normal resident of human metabolism, not a foreign substance.

For commercial production, manufacturers start with ascorbic acid and oxidize it with hydrogen peroxide in the presence of calcium carbonate, which yields calcium threonate. To make the magnesium form used in supplements, calcium is swapped out for magnesium by adding magnesium carbonate and oxalic acid.² The end product, magnesium L-threonate, is sold under various brand names, the most well-known being Magtein. Because threonic acid is derived from vitamin C and is already present in the body, its safety profile has been relatively easy to establish, though the doses in supplement form are considerably higher than what you would produce on your own.

Why Magnesium L-Threonate Gets the Attention

Most magnesium supplements, whether they contain magnesium oxide, citrate, or sulfate, raise magnesium levels in your blood effectively enough. The problem is the brain. The central nervous system is protected by the blood-brain barrier, a tightly regulated layer of cells that keeps most circulating molecules out. Magnesium from conventional supplements does not meaningfully increase the concentration of magnesium in cerebrospinal fluid, the liquid that bathes the brain and spinal cord. In a mouse study, magnesium sulfate given systemically failed to raise cerebrospinal fluid magnesium at all, while magnesium L-threonate succeeded.³ A separate comparison in rats found that oral magnesium L-threonate raised cerebrospinal fluid magnesium concentrations by roughly 7 to 15 percent over 24 days, while other magnesium forms, including chloride, citrate, glycinate, and gluconate, did not produce a comparable increase.⁴

The threonate portion of the molecule is thought to be what makes this possible. Research in cultured neurons showed that raising threonate levels on its own, independent of magnesium, boosted the expression of a specific type of receptor involved in learning and memory, boosted the energy output of mitochondria inside neurons, and increased the density of functional connections between nerve cells.⁵ In other words, threonate is not just a passive shuttle for magnesium. It appears to have its own biological activity in nerve tissue, raising intracellular magnesium concentrations and triggering downstream effects on synapse formation.

Effects on Synapses and Brain Signaling

The brain benefits attributed to magnesium L-threonate largely revolve around synaptic plasticity, which is the ability of connections between neurons to strengthen or weaken in response to experience. That process underpins learning and memory. When magnesium levels inside neurons rise, one documented effect is an increase in a particular subunit of the NMDA receptor, called NR2B. In rats given chronic magnesium L-threonate treatment, NR2B expression in the hippocampus increased by about 60 percent compared to controls, while other receptor subunits stayed the same.⁶ The NR2B subunit is associated with longer-lasting signals at synapses, which is one reason it keeps showing up in learning research.

Why does this matter for the brain in disease states? In mouse models of Alzheimer’s disease, magnesium L-threonate treatment reduced amyloid plaque buildup, prevented synapse loss, and preserved memory performance. At the molecular level, raising brain magnesium prevented a cascade of damage that amyloid proteins normally trigger: it kept NMDA receptor signaling intact and tamped down an enzyme called BACE1, which is involved in producing the toxic amyloid fragments in the first place.⁷ Remarkably, the treatment showed benefit even when started at an advanced stage of the disease-like pathology in these mice. A separate Alzheimer’s mouse study confirmed that magnesium L-threonate reduced hippocampal neuron death and suppressed amyloid-beta accumulation along with a protein called NOX4 that drives oxidative damage.⁸

When magnesium L-threonate was combined with environmental enrichment (essentially, more stimulating living conditions for the mice), the cognitive improvements were greater than with either intervention alone, whether the treatment started before or after disease onset.⁹ That finding suggests that raising brain magnesium and providing cognitive stimulation may have complementary mechanisms rather than overlapping ones.

What the Human Trials Actually Show

Animal results are encouraging but they are not proof that the same thing happens in people. Human evidence for magnesium L-threonate is still thin, consisting of a handful of controlled trials and several open-label studies. The most rigorous published trial to date was a randomized, double-blind, placebo-controlled study in adults that found the supplement group showed greater improvement in overall cognitive performance, as measured by a standardized composite score, with the largest effects on working memory and episodic memory.¹⁰

That is a real finding, and it aligns with the animal data, but a few things temper the excitement. The effect sizes, while statistically significant, were modest. The trial was funded by the company that makes Magtein. And there is no large, independent replication yet. This places magnesium L-threonate in a familiar zone for supplements: plausible mechanism, promising early data, but not yet the kind of evidence base you would see for, say, a prescription drug approved for cognitive decline. That gap should narrow as more trials are completed, but for now, the honest summary is “encouraging but preliminary” when it comes to human cognition.

Sleep Quality and Daytime Functioning

A separate randomized controlled trial tested magnesium L-threonate specifically for sleep in adults who reported sleep difficulties. Using both wearable ring-based tracking and subjective questionnaires, the researchers found that the supplement group showed meaningful improvements in deep sleep, REM sleep, and light sleep duration compared to placebo. Daytime measures improved as well: participants reported better energy, mood, mental alertness, and productivity, along with less grouchiness upon waking.¹¹

The sleep connection makes physiological sense. Magnesium is involved in regulating the parasympathetic nervous system, the branch that helps you relax, and it also modulates the activity of NMDA receptors, which need to quiet down for sleep to consolidate properly. Whether threonate specifically adds something beyond what a well-absorbed oral magnesium supplement would provide for sleep is harder to say. The blood-brain-barrier argument is less critical for sleep regulation than for, say, synaptic plasticity, because some of magnesium’s calming effects operate through peripheral mechanisms (muscle relaxation, heart rate regulation) that do not require brain penetration. Still, the trial data show improvements on both objective and subjective sleep measures, so the compound does appear to help, at least in people who start out sleeping poorly.

A Parkinson’s Disease Connection

Beyond Alzheimer’s models, magnesium L-threonate has been tested in mice with chemically induced Parkinson’s-like symptoms. In that study, mice treated with a toxin that destroys dopamine-producing neurons showed motor deficits and significant neuron loss. The group receiving magnesium L-threonate had elevated cerebrospinal fluid magnesium and showed reduced motor deficits and less dopamine neuron death compared to untreated mice, while the group receiving magnesium sulfate at the same dose showed no such protection.¹² This reinforces the idea that getting magnesium into the central nervous system is the rate-limiting step, and that threonate specifically solves that problem. No human Parkinson’s trials have been published yet.

Threonic Acid Beyond the Brain

Most of the commercial interest in threonic acid is tied to its magnesium shuttle role, but the molecule has shown biological activity in at least two other areas that have nothing to do with the nervous system.

In bone and dental tissue research, calcium threonate has been studied for its effect on mineralization. When human bone-forming cells were grown with ascorbic acid spiked with calcium threonate, they produced significantly more mineralized tissue and collagen than cells treated with plain ascorbic acid alone.¹³ This is an in-vitro finding, so drawing direct conclusions about bone health in living people would be premature, but it raises the possibility that threonate plays a supporting role in how vitamin C contributes to bone formation, beyond just being a breakdown product.

Hair loss research has also intersected with threonic acid. A cell-culture study investigated whether L-threonate could counteract the effects of dihydrotestosterone (DHT), the hormone that drives pattern baldness. DHT triggers production of a protein called DKK-1 in hair follicle cells, and DKK-1 then inhibits the growth of the outer root sheath cells that keep hair follicles active. Threonate significantly suppressed DHT-induced DKK-1 expression and reversed the growth inhibition of those keratinocytes.¹⁴ Again, this is lab-dish science, not a clinical trial, but it is an interesting demonstration that threonic acid has receptor-level biological effects outside the nervous system. No topical threonate hair products have reached the market based on this work.

Safety and Dosing

The European Food Safety Authority (EFSA) evaluated magnesium L-threonate as a novel food and concluded that it is safe at the proposed maximum daily intake, which corresponds to about 2,730 milligrams of L-threonate per day. This assessment leaned on earlier safety reviews of calcium L-threonate at a similar daily threonate load (about 2,700 milligrams). Subchronic toxicity studies in animals had identified adverse effects at high doses, but EFSA determined those effects were caused by excessive calcium, not by threonate itself. The safety margins between the no-adverse-effect levels in animals and the proposed human doses were considered sufficient.¹⁵ The endogenous nature of threonate, the fact that your body already makes and handles it as a normal part of vitamin C metabolism, was a significant factor in that assessment.

In practice, supplement labels typically recommend doses that deliver around 144 milligrams of elemental magnesium per day from magnesium L-threonate, which means the accompanying threonate dose is much larger since magnesium makes up a relatively small fraction of the compound’s molecular weight. Side effects reported in trials have been mild and mainly gastrointestinal, consistent with what you would expect from any oral magnesium supplement. People with kidney disease should be cautious with any supplemental magnesium, and anyone on medications that interact with magnesium (certain antibiotics, bisphosphonates, or diuretics) should check with a pharmacist.

Threonic Acid as a Metabolic Marker

Because threonic acid is produced when vitamin C is consumed and metabolized, plasma levels of threonate can serve as a biomarker reflecting vitamin C status and oxidative stress. A metabolomics study tracking smokers who switched to electronic nicotine delivery systems found that plasma threonate levels rose after the switch, alongside improvements in other markers of vitamin C and vitamin A metabolism.¹⁶ The interpretation is that smoking depletes vitamin C through massive oxidative demand, so less smoking means more vitamin C circulating and, consequently, more of its metabolites, including threonate, showing up in the blood.

This biomarker application is still niche, but it highlights something easy to overlook: threonic acid is not just a supplement ingredient. It is a natural part of how your body processes one of its most essential vitamins. Every time you eat an orange or take a vitamin C tablet, a fraction of that ascorbic acid ends up as threonic acid. The supplement industry has found a way to exploit threonate’s unusual ability to escort magnesium into the brain, but the molecule itself has been doing quiet metabolic work in the human body for as long as humans have eaten fruit.

Common Misconceptions Worth Correcting

The first misconception is that magnesium L-threonate is the only supplement that raises brain magnesium. It is the most studied for this purpose, and the animal data clearly show it outperforms several other forms. But the claim that no other magnesium compound can cross the blood-brain barrier is likely an oversimplification. The barrier is not perfectly impermeable to all magnesium forms; it is a matter of degree. What the data support is that threonate does this more efficiently and at lower doses than the alternatives tested so far.

The second is that threonic acid and magnesium L-threonate are interchangeable terms. They are not. Threonic acid is the organic acid. Magnesium L-threonate is a salt that combines that acid with magnesium. When you take a magnesium L-threonate supplement, both the magnesium and the threonate contribute to the effects, and as the neuron culture research showed, threonate has independent biological activity on synapse density and receptor expression even without added magnesium.¹⁷ The distinction matters because it opens the question of whether threonate alone, without the magnesium, might be useful in some contexts. That question has barely been explored clinically.

The third misconception is that the cognitive benefits are proven in humans with dementia. All of the Alzheimer’s and Parkinson’s data come from mouse models. The human trials have been conducted in generally healthy adults or adults with self-reported complaints, not in patients with diagnosed neurodegenerative disease. The leap from “reversed plaques and preserved memory in transgenic mice” to “treats Alzheimer’s in people” is enormous, and many promising compounds have failed to make that jump. The honest framing is that magnesium L-threonate is a plausible candidate for further research in neurodegeneration, not an established treatment.